Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019
Wenbin Li(Sun Yat-sen University), Juan Jiao, Lei Guo(Guangdong Provincial People's Hospital), Zebing Liu, Jia Li(Capital Medical University), Ai‐Yan Xing(Shandong University), Xuefeng Bai, Yi Shi(Nankai University), Xianhua Xu(Hainan Medical University), Xiumei Duan, Nanying Che, Guozhong Jiang(First Affiliated Hospital of Zhengzhou University), Yan Wu(Second Affiliated Hospital of Zhejiang University), Lian He(Vision Medicals (China)), Ziguang Xu(National Medical Products Administration), Yanping Hu(Chinese People's Liberation Army), Guohua Yu(Qingdao University), Shaoming Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jie Lin(Fujian Medical University), Qianming Bai(Shanghai Medical College of Fudan University), Xinghua Zhu(Chang'an University), Tian Qiu(Changi General Hospital), Dan Su(Second Affiliated Hospital of Xi'an Jiaotong University), Bing Wei(Henan University of Engineering), Hong Li(University of British Columbia Hospital), Liping Liu(Beijing Tongren Hospital), Nan Liu(Southwest Medical University), Yan Li(Shanghai Jiao Tong University), Weihua Li(Fujian Medical University), Xuemei Li, Xiaoyan Li(University of Wisconsin–Madison), Jie Ma(Zhengzhou University), Shujun Zhang(Fujian Normal University), Lei Dong(Beijing Tongren Hospital), Jie He(First Affiliated Hospital of Jinan University), Fang Li(Changzhi Medical College), Chao Xu(National Medical Products Administration), Jie Huang(Sun Yat-sen University), Yanfeng Xi, Wentao Huang, Zhihui Yang, Yunfeng Lv(Changchun Normal University), Hongxue Meng(Harbin Medical University), Qian Cui(University of Electronic Science and Technology of China), Xiaotong Hu(Chongqing University of Technology), Meihong Yao(Fujian Medical University), Ling Xie, Fang Guo(National Medical Products Administration), Xiaoyan Zhou(Shanghai Medical College of Fudan University), Jianming Ying(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 12
Related Papers
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Cancer registration in China and its role in cancer prevention and control
|The Lancet Oncology|2020|501
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415